Viragen Reports that Peptide Agreement Expires
Viragen, Inc. announced that it has elected not to exercise an exclusive option to license VG104, the IEP 11 peptide, from the University of Miami. The IEP 11 peptide was being researched as a potential cancer therapeutic. In light of Viragen's decision, the option has expired and all development activities relating to VG104 have been discontinued.
Charles A. Rice, Viragen's President & CEO, commented, "We appreciate the collaborative efforts of the University of Miami and their work with us over the past few years, and we wish them well with their ongoing research. No further funding will be committed to this project, and we will direct our resources to our priority projects. Moving forward, as we continue in various stages of negotiations with potential partners, we expect to implement additional changes to rebuild Viragen."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.